(Q83944098)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19479418%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

review article

1 reference

title

[Management of chemotherapy-induced emesis: what is the standard after 20 years of clinical research] (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19479418%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

author name string

A Du Bois

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19479418%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

publication date

1 January 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19479418%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19479418%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

volume

93 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19479418%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

page(s)

3-17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19479418%20AND%20SRC:MED&resulttype=core&format=json

Comparison of intermittent ondansetron versus continuous infusion metoclopramide used with standard combination antiemetics in control of acute nausea induced by cisplatin chemotherapy.

29 January 2020

cites work

1 reference

12 December 2020

Double-blind crossover trial of single vs. divided dose of metoclopramide in a combined regimen for treatment of cisplatin-induced emesis

1 reference

12 December 2020

Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. The Granisetron Study Group

1 reference

12 December 2020

Acute and anticipatory emesis in breast cancer patients

1 reference

12 December 2020

High-dose versus low-dose metoclopramide in the prevention of cisplatin-induced emesis. A randomized crossover study in patients with ovarian carcinoma

1 reference

12 December 2020

Identification of enteramine, the specific hormone of the enterochromaffin cell system, as 5-hydroxytryptamine.

1 reference

12 December 2020

An open multicentre study of tropisetron for cisplatin-induced nausea and vomiting.

1 reference

12 December 2020

Antiemetic therapy: a review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol

1 reference

12 December 2020

Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo

1 reference

12 December 2020

GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis

1 reference

12 December 2020

Betamethasone-dixyrazine versus betamethasone-metoclopramide as antiemetic treatment of cisplatin-doxorubicin-induced nausea in ovarian carcinoma patients.

1 reference

12 December 2020

High-dose dexamethasone for prevention of cis-platin-induced vomiting

1 reference

12 December 2020

Prevention of nausea and vomiting in cisplatin-treated patients by a selective 5-hydroxytryptamine (5-HT3) receptor antagonist, ICS 205-930.

1 reference

12 December 2020

Conditioned aversive responses in cancer chemotherapy patients: theoretical and developmental analysis

1 reference

12 December 2020

Discrete lesions of the area postrema abolish radiation-induced emesis in the dog.

1 reference

12 December 2020

Cisplatin and emesis: aspects of treatment and a new trial for delayed emesis using oral dexamethasone plus ondansetron beginning at 16 hours after cisplatin

1 reference

12 December 2020

Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis

1 reference

12 December 2020

Tropisetron (Navoban) in the prevention of chemotherapy-induced nausea and vomiting--the Nordic experience.

1 reference

12 December 2020

Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Italian Group For Antiemetic Research

1 reference

12 December 2020

PREVENTION OF EMESIS IN PATIENTS RECEIVING CYTOTOXIC DRUGS BY GR38032F, A SELECTIVE 5-HT3 RECEPTOR ANTAGONIST

1 reference

12 December 2020

Tropisetron-dexamethasone combination for carboplatin-induced emesis

1 reference

12 December 2020

An open study to assess the safety, tolerance and pharmacokinetics of an intravenous infusion of granisetron given at 3 mg over 30 s in patients receiving chemotherapy for malignant disease

1 reference

12 December 2020

Acute and Delayed Emesis after Cisplatin-Based Regimen: Description and Prevention

1 reference

12 December 2020

Ondansetron in the prophylaxis of nausea and vomiting induced by carboplatin combination chemotherapy

1 reference

12 December 2020

A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. The Granisetron Study Group

1 reference

12 December 2020

Emetic control in breast cancer patients receiving iv CMF

1 reference

12 December 2020

Fundamental studies with cisplatin

1 reference

12 December 2020

Randomized, double-blind cross-over study of acute cisplatin-induced nausea and vomiting, comparing a new schedule of the combination of metoclopramide and methylprednisolone versus metoclopramide alone

1 reference

12 December 2020

A randomized double-blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and lorazepam in the prevention of emesis due to cisplatin-based chemotherapy

1 reference

12 December 2020

The use of methylprednisolone and metoclopramide in control of emesis in patients receiving cis-platinum

1 reference

12 December 2020

Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens

1 reference

12 December 2020

Efficacy of ondansetron treatment with different timing schedules: a randomized double-blind study

1 reference

12 December 2020

Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil.

1 reference

12 December 2020

A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy. The Granisetron Study Group

1 reference

12 December 2020

Control of cisplatin-induced delayed emesis with metoclopramide and dexamethasone: a randomized controlled trial.

1 reference

12 December 2020

Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: a multicentre, double-blind, double-dummy, randomised, parallel-group study. Emesis Study Group for Ondansetron and Granisetron in Breast Ca

1 reference

12 December 2020

Ondansetron plus dexamethasone: an effective combination in high-dose cisplatin therapy. The Italian Oncology Group for Clinical Research

1 reference

12 December 2020

A comparison of metoclopramide vs. droperidol/phenobarbital for emesis induced by chemotherapy

1 reference

12 December 2020

[Effectiveness and tolerance of Navoban (5HT3-receptor antagonist tropisetron) in prevention of cytostatic drug-induced nausea and vomiting in patients with breast carcinomas and gynecological malignancies]

1 reference

12 December 2020

Persistent anticipatory nausea, vomiting, and anxiety in cured Hodgkin's disease patients after completion of chemotherapy

1 reference

12 December 2020

5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy—A randomised study

1 reference

12 December 2020

Oral medium-dosed metoclopramide versus placebo as highly effective antiemetic prophylaxis in in- and outpatients on noncisplatin chemotherapy

1 reference

12 December 2020

Ondansetron for the prevention of emesis induced by high-dose cisplatin. A multi-center dose-response study

1 reference

12 December 2020

Comparison of antiemetic efficacy of domperidone, metoclopramide, and dexamethasone in patients receiving outpatient chemotherapy regimens

1 reference

12 December 2020

Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone

1 reference

12 December 2020

Characterization of the role of calcium and sodium channels in the stimulus secretion coupling of 5-hydroxytryptamine release from porcine enterochromaffin cells

1 reference

12 December 2020

High-dose metoclopramide and chlorpromazine in the treatment of cisplatin-induced emesis

1 reference

12 December 2020

Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population

1 reference

12 December 2020

Efficacy of two oral dose regimens of granisetron

1 reference

12 December 2020

Efficacy of oral ondansetron, a selective antagonist of 5-HT3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Ondansetron Study Group

1 reference

12 December 2020

Dexamethasone improves the efficacy of granisetron in the first 24 h following high-dose cisplatin chemotherapy

1 reference

12 December 2020

Efficacy of Ondansetron and Lorazepam in controlling emesis associated with cytotoxic chemotherapy

1 reference

12 December 2020

Control of nausea and vomiting by granisetron in ovarian cancer patients treated with different cisplatin-based regimens

1 reference

12 December 2020

Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. The Ondansetron Study Group

1 reference

12 December 2020

A randomized, double-blind, multicentre study comparing daily 2 and 5 mg of tropisetron for the control of nausea and vomiting induced by low-dose cisplatin- or non-cisplatin-containing chemotherapy

1 reference

12 December 2020

International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin)

1 reference

12 December 2020

5-HT3 receptor antagonists in the control of cisplatin-induced delayed emesis

1 reference

12 December 2020

EFFECTS OF DRUGS ON VERTEBRATE MECHANORECEPTORS

1 reference

12 December 2020

A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis

1 reference

12 December 2020

MDL 72222: a potent and highly selective antagonist at neuronal 5-hydroxytryptamine receptors.

1 reference

12 December 2020

Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin

1 reference

12 December 2020

Motion sickness adaptation: a neural mismatch model

1 reference

12 December 2020

Comparison of Granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer. A randomized controlled trial

1 reference

12 December 2020

Optimum anti-emetic therapy for cisplatin induced emesis over repeat courses: ondansetron plus dexamethasone compared with metoclopramide, dexamethasone plus lorazepam.

1 reference

12 December 2020

Role of maintenance oral dexamethasone in prophylaxis of delayed emesis caused by moderately emetogenic chemotherapy

1 reference

12 December 2020

Ondansetron (GR38032) in the prophylaxis of acute and delayed cisplatin-induced emesis

1 reference

12 December 2020

Pharmacological characterization of 5-hydroxytryptamine-induced depolarization of the rat isolated vagus nerve

1 reference

12 December 2020

Refractory vomiting with cisplatin therapy. Prospective study with the serotonin receptor antagonist GR 38032F

1 reference

12 December 2020

Randomized crossover comparison of high-dose intravenous metoclopramide versus a five-drug antiemetic regimen.

1 reference

12 December 2020

A randomized trial of metoclopramide and a combination of dexamethasone and lorazepam for prevention of chemotherapy-induced vomiting

1 reference

12 December 2020

Delayed emesis following high-dose cisplatin: a double-blind randomised comparative trial of ondansetron (GR 38032F) versus placebo

1 reference

12 December 2020

A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. The Granisetron Study Group

1 reference

12 December 2020

The role of serotonin as a mediator of emesis induced by different stimuli

1 reference

12 December 2020

Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial

1 reference

12 December 2020

Mechanisms of vomiting induced by serotonin-3 receptor agonists in the cat: effect of vagotomy, splanchnicectomy or area postrema lesion

1 reference

12 December 2020

Plasticity of emesis to a 5-HT3 agonist: effect of order of visceral nerve cuts

1 reference

12 December 2020

Reduction of carboplatin induced emesis by ondansetron

1 reference

12 December 2020

High-dose intravenous metoclopramide versus combination high-dose metoclopramide and intravenous dexamethasone in preventing cisplatin-induced nausea and emesis: a single-blind crossover comparison of antiemetic efficacy

1 reference

12 December 2020

Comparison of Ondansetron with Customary Treatment in the Prophylaxis of Nausea and Emesis Induced by Non-Cisplatin Containing Chemotherapy

1 reference

12 December 2020

Compassionate use of a 5-HT3-receptor antagonist, tropisetron, in patients refractory to standard antiemetic treatment

1 reference

12 December 2020

5-HT3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret

1 reference

12 December 2020

Efficacy of Ondansetron (Gr 38032F) and the Role of Serotonin in Cisplatin-Induced Nausea and Vomiting

1 reference

12 December 2020

Low-dose metoclopramide versus methylprednisolone in controlling chemotherapy induced nausea and vomiting

1 reference

12 December 2020

Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy

1 reference

12 December 2020

Ondansetron: prevention of nausea & vomiting in cisplatin based chemotherapy

1 reference

12 December 2020

Optimal combination therapy with Navoban (tropisetron) in patients with incomplete control of chemotherapy-induced nausea and vomiting. The Belgian Navoban Group.

1 reference

12 December 2020

Is Navoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induced emesis? The French Navoban Study Group

1 reference

12 December 2020

Antiemetic efficacy of nabilone and dexamethasone: a randomized study of patients with lung cancer receiving chemotherapy

1 reference

12 December 2020

Dose-ranging antiemetic trial of high-dose oral metoclopramide

1 reference

12 December 2020

Randomized open cross-over trial between Metoclopramide (MCP) and dexamethazone (DXM) for the prevention of cisplatin-induced nausea and vomiting

1 reference

12 December 2020

A pilot study of metoclopramide, dexamethasone, diphenhydramine and lorazepam in prevention of nausea and vomiting in cisplatin-treated male patients.

1 reference

12 December 2020

Oral treatment with ondansetron in an outpatient setting

1 reference

12 December 2020

Activation of vagal gastric mechanoreceptors by cholecystokinin

1 reference

12 December 2020

Analysis of cumulative probabilities shows that the efficacy of 5HT3 antagonist prophylaxis is not maintained

1 reference

12 December 2020

Intravenous metoclopramide: prevention of chemotherapy-induced nausea and vomiting. A preliminary evaluation.

1 reference

12 December 2020

Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatinum: a double blind study

1 reference

12 December 2020

Ondansetron versus metoclopramide as antiemetic treatment during cisplatin-based chemotherapy. A prospective study with special regard to regard to electrolyte imbalance

1 reference

12 December 2020

Improved control of cisplatin-induced emesis with a combination of high doses of methylprednisolone and metoclopramide: a single-blind randomized trial

1 reference

12 December 2020

Prevention of chemotherapy-induced nausea and emesis in patients responding poorly to previous antiemetic therapy. Comparing tropisetron with optimised standard antiemetic therapy

1 reference

12 December 2020

Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents.

1 reference

12 December 2020

Superiority of Granisetron to Dexamethasone Plus Prochlorperazine in the Prevention of Chemotherapy-Induced Emesis

1 reference

12 December 2020

A comparison of ondansetron with alizapride plus methylprednisolone in the control of cisplatin-induced emesis. The French Pneumology Group for the Ondansetron Study

1 reference

12 December 2020

Long-term results of the anti-emetic effectiveness of the 5-HT3 antagonist ondansetron

1 reference

12 December 2020

Persistence of efficacy of three antiemetic regimens and prognostic factors in patients undergoing moderately emetogenic chemotherapy. Italian Group for Antiemetic Research

1 reference

12 December 2020

Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer

1 reference

12 December 2020

Methylprednisolone enhances the efficacy of ondansetron in acute and delayed cisplatin-induced emesis over at least three cycles. Ondansetron Study Group

1 reference

12 December 2020

A randomized cross-over trial of granisetron and dexamethasone versus granisetron alone: the role of dexamethasone on day 1 in the control of cisplatin-induced delayed emesis

1 reference

12 December 2020

A prospective randomized double-blind crossover study comparing the antiemetic activity of alizapride and metoclopramide in patients receiving cisplatin chemotherapy

1 reference

12 December 2020

An open randomised cross-over study on granisetron versus ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-containing regimens.

1 reference

12 December 2020

Alizapride alone or alizapride-dexamethasone compared with metoclopramide-dexamethasone in patients at high risk of acute emesis after cisplatin. A randomized cross-over study

1 reference

12 December 2020

A comparison of the antiemetic efficacy of prochlorperazine and metoclopramide for the treatment of cisplatin-induced emesis: a prospective, randomized, double-blind study

1 reference

12 December 2020

Methylprednisolone as an antiemetic drug. A randomised double blind study.

1 reference

12 December 2020

Methylprednisolone in cis-platinum induced nausea and emesis: a placebo-controlled trial

1 reference

12 December 2020

The effect of administration rate on cisplatin-induced emesis

1 reference

12 December 2020

Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. The Ondansetron and Granisetron Emesis Study Group

1 reference

12 December 2020

A randomized trial of high dose bolus metoclopramide versus low-dose continuous infusion metoclopramide in the prevention of cisplatin-induced emesis

1 reference

12 December 2020

Tissue 5-hydroxytryptamine and urinary 5-hydroxyindoleacetic acid after partial or total removal of the gastro-intestinal tract in the rat

1 reference

12 December 2020

Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Em

1 reference

12 December 2020

Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin

1 reference

12 December 2020

Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: a double blind comparative study with ondansetron tablets

1 reference

12 December 2020

Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomised trial of antiemetics.

1 reference

12 December 2020

Results of a randomized double-blind crossover trial of scopolamine versus placebo administered by transdermal patch for the control of cisplatin-induced emesis

1 reference

12 December 2020

Use of Triangular Waveforms of Angular Velocity in the Study of Vestibular Function

1 reference

12 December 2020

Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron

1 reference

12 December 2020

Control of emesis by intravenous granisetron in breast cancer patients treated with 5-FU, epirubicin and cyclophosphamide

1 reference

12 December 2020

Comparison of intermittent versus continuous infusion metoclopramide in control of acute nausea induced by cisplatin chemotherapy.

1 reference

12 December 2020

Functional localization of central coordinating mechanism for emesis in cat

1 reference

12 December 2020

Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide

1 reference

12 December 2020

Difference in persistence of efficacy of two antiemetic regimens on acute emesis during cisplatin chemotherapy. The Italian Group for Antiemetic Research

1 reference

12 December 2020

Hyperemesis gravidarum: a particular problem for Pacific Islanders

1 reference

12 December 2020

Increased gut cholinergic activity and antagonism of 5-hydroxytryptamine M-receptors by BRL 24924: potential clinical importance of BRL 24924.

1 reference

12 December 2020

A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. The Swons Gynaecological Cancer Group.

1 reference

12 December 2020

Ondansetron (OND) vs granisetron (GRA) in the control of chemotherapy induced acute emesis

1 reference

12 December 2020

Small intestinal mucosal toxicity of cis-platinum--comparison of toxicity with platinum analogues and dexamethasone

1 reference

12 December 2020

Activity of a new antiemetic agent: alizapride. A randomized double-blind crossover controlled trial

1 reference

12 December 2020

Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. A prospective randomized trial

1 reference

12 December 2020

Oral metoclopramide with or without diphenhydramine: potential for prevention of late nausea and vomiting induced by cisplatin

1 reference

12 December 2020

The Natural Course of Emesis After Carboplatin Treatment

1 reference

12 December 2020

Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis

1 reference

12 December 2020

Comparison of the efficacy of tropisetron versus a metoclopramide cocktail based on the intensity of cisplatin-induced emesis

1 reference

12 December 2020

Ondansetron compared with ondansetron plus metoclopramide in the prevention of cisplatin-induced emesis

1 reference

12 December 2020

Double-blind, randomized trial for the control of delayed emesis in patients receiving cisplatin: comparison of placebo vs. adrenocorticotropic hormone (ACTH)

1 reference

12 December 2020

Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study

1 reference

12 December 2020

The alteration of serotonin metabolism to 5-hydroxytryptophol by ethanol ingestion in man

1 reference

12 December 2020

Antiemetic efficacy of high-dose intravenous metoclopramide and dexamethasone in patients receiving cisplatin-based chemotherapy: a randomized controlled trial.

1 reference

12 December 2020

Randomised trial for the prevention of delayed emesis in patients receiving high-dose cisplatin

1 reference

12 December 2020

Double-blind crossover study of the antiemetic efficacy of high-dose dexamethasone versus high-dose metoclopramide

1 reference

12 December 2020

Comparison of the antiemetic efficacy of two high-dose benzamides, metoclopramide and alizapride, against cisplatin-induced emesis

1 reference

12 December 2020

Serum vasoconstrictor (serotonin) the presence of creatinine in the complex; a proposed structure of the vasoconstrictor principle.

1 reference

12 December 2020

CURRENT status of therapy in nausea and vomiting of pregnancy

1 reference

12 December 2020

Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Instit

1 reference

12 December 2020

Effects of the benzodiazepine receptor agonist midazolam and antagonist flumazenil on 5-hydroxytryptamine release from guinea-pig intestine in vitro. Indirect support for a "natural" benzodiazepine-like substance in the intestine.

1 reference

12 December 2020

The efficacy of GR38032F, an antagonist of 5-hydroxytryptamine-3 (5-HT3) in the prophylaxis of cisplatin (CDDP)-induced nausea and vomiting

1 reference

12 December 2020

Physiology and pharmacology of vomiting

1 reference

12 December 2020

Locus of emetic action following irradiation

1 reference

12 December 2020

The addition of ondansetron to the combination of metoclopramide, dexamethasone, and lorazepam did not improve vomiting prevention in patients receiving high-dose cisplatin

1 reference

12 December 2020

Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life

1 reference

12 December 2020

Dose comparison of tropisetron (Navoban) 5 mg and 10 mg orally in the prophylaxis of dacarbazine-induced nausea and emesis

1 reference

12 December 2020

Prophylaxis of delayed nausea and vomiting after cancer chemotherapy

1 reference

12 December 2020

Comparison of ondansentron (GR 38032F) versus ondansentron plus alprazolam as antiemetic prophylaxis during cisplatin-containing chemotherapy

1 reference

12 December 2020

Randomized, double-blind, cross-over study comparing prochlorperazine and lorazepam with high-dose metoclopramide and lorazepam for the control of emesis in patients receiving cytotoxic chemotherapy

1 reference

12 December 2020

Blockade of serotonin receptors on autonomic neurones by (−)-cocaine and some related compounds

1 reference

12 December 2020

Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group.

1 reference

12 December 2020

Studies on mechanism of retching and vomiting in dogs. Effect of peripheral dopamine blocker on myoelectric changes in antrum and upper small intestine

1 reference

12 December 2020

Two kinds of tryptamine receptor

1 reference

12 December 2020

Progress in the control of acute and delayed emesis induced by cisplatin

1 reference

12 December 2020

The antiemetic activity of high-dose alizapride and high-dose metoclopramide in patients receiving cancer chemotherapy: a prospective, randomized, double-blind trial.

1 reference

12 December 2020

Antiemetic properties of the 5HT3-receptor antagonist, GR38032F

1 reference

12 December 2020

Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting.

1 reference

12 December 2020

Cinnarizine for prevention of nausea and vomiting during platin chemotherapy

1 reference

12 December 2020

Cisplatin-induced vomiting eliminated by ablation of the area postrema in cats

1 reference

12 December 2020

A comparison of droperidol and metoclopramide in the treatment of nausea and vomiting during cis-platinum polichemotherapy in ovarian carcinoma

1 reference

12 December 2020

Plasticity of autonomic control of emesis in irradiated ferrets.

1 reference

12 December 2020

Anti-emetic profile of a non-peptide neurokinin NK1 receptor antagonist, CP-99,994, in ferrets

1 reference

12 December 2020

Antiemetic Efficacy of Dexamethasone Therapy in Patients Receiving Cancer Chemotherapy

1 reference

12 December 2020

Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo

1 reference

12 December 2020

A Phase II study of ondansetron as antiemetic prophylaxis in patients receiving carboplatin for advanced ovarian cancer

1 reference

12 December 2020

Cisplatin increases the release of 5-hydroxytryptamine (5-HT) from the isolated vascularly perfused small intestine of the guinea-pig: Involvement of 5-HT3 receptors

1 reference

12 December 2020

The pattern of emesis following high-dose cyclophosphamide and the anti-emetic efficacy of ondansetron

1 reference

12 December 2020

Ondansetron (GR38032F) plus dexamethasone: effective anti-emetic prophylaxis for patients receiving cytotoxic chemotherapy

1 reference

12 December 2020

Binding of the 5-HT3 ligand, [3H]GR65630, to rat area postrema, vagus nerve and the brains of several species

1 reference

12 December 2020

A controlled clinical trial of the addition of transdermal scopolamine to a standard metoclopramide and dexamethasone antiemetic regimen

1 reference

12 December 2020

Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Re

1 reference

12 December 2020

A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy

1 reference

12 December 2020

Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.

1 reference

12 December 2020

'Vomiting center' reanalyzed: an electrical stimulation study.

1 reference

12 December 2020

A randomised trial of dexamethasone, lorazepam and prochlorperazine for emesis in patients receiving chemotherapy

1 reference

12 December 2020

Granisetron plus dexamethasone in moderately emetogenic chemotherapy: evaluation of activity during three consecutive courses of chemotherapy

1 reference

12 December 2020

Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine

1 reference

12 December 2020

The 5-HT3 receptor ligand, [3H]BRL 43694, binds to presynaptic sites in the nucleus tractus solitarius of the rat

1 reference

12 December 2020

Comparison of four antiemetic regimens for the treatment of cisplatin-induced vomiting

1 reference

12 December 2020

Reserpine, para-chlorophenylalanine and fenfluramine antagonise cisplatin-induced emesis in the ferret

1 reference

12 December 2020

A prospective, randomized double-blind trial comparing metoclopramide alone with metoclopramide plus dexamethasone in preventing emesis induced by high-dose cisplatin

1 reference

12 December 2020

Double-blind controlled trial of the antiemetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with i.v. CMF.

1 reference

12 December 2020

Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetogenic potential of the chemotherapy regimen

1 reference

12 December 2020

Antiemetic combination for cisplatin-induced emesis. Results from a controlled study

1 reference

12 December 2020

Oncologists' views of cancer patient noncompliance.

1 reference

12 December 2020

On the receiving end--patient perception of the side-effects of cancer chemotherapy.

1 reference

12 December 2020

Intestinal myoelectric activity after activation of central emetic mechanism.

1 reference

12 December 2020

Differential interactions of traditional and novel antiemetics with dopamine D2 and 5-hydroxytryptamine3 receptors

1 reference

12 December 2020

A double-blind trial comparing antiemetic efficacy and toxicity of metoclopramide versus methylprednisolone versus domperidone in patients receiving doxorubicin chemotherapy alone or in combination with other antiblastic agents.

1 reference

12 December 2020

Dose-finding study of tropisetron in cisplatin-induced nausea and vomiting

1 reference

12 December 2020

Effective control of cisplatin-induced nausea using high-dose steroids and droperidol.

1 reference

12 December 2020

The enteric neural receptor for 5-hydroxytryptamine

1 reference

12 December 2020

Antiemetic activity of oral lorazepam in addition to methylprednisolone and metoclopramide in the prophylactic treatment of vomiting induced by cisplatin. A double-blind, placebo-controlled study with crossover design

1 reference

12 December 2020

Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin.

1 reference

12 December 2020

Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research.

1 reference

12 December 2020

Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting

1 reference

12 December 2020

Tropisetron plus haloperidol to ameliorate nausea and vomiting associated with high-dose alkylating agent cancer chemotherapy

1 reference

12 December 2020

Comparison of the emetogenic potential between cisplatin and carboplatin in combination with alkylating agents

1 reference

12 December 2020

Experimental motion sickness in dogs; importance of labyrinth and vestibular cerebellum.

1 reference

12 December 2020

Treatment with para-chlorophenylalanine antagonises the emetic response and the serotonin-releasing actions of cisplatin in cancer patients

1 reference

12 December 2020

Dexamethasone vs. placebo for cisplatin-induced emesis. A randomized cross-over trial

1 reference

12 December 2020

Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism

1 reference

12 December 2020

Chlorpromazine and dexamethasone versus high-dose metoclopramide and dexamethasone in patients receiving cancer chemotherapy, particularly cis-platinum: a prospective randomized crossover study

1 reference

12 December 2020

Comparison of metoclopramide and metoclopramide plus dexamethasone for complete protection from cisplatinum-induced emesis

1 reference

12 December 2020

Antiemetic activity of two different high doses of metoclopramide in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research

1 reference

12 December 2020

A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis

1 reference

12 December 2020

The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo

1 reference

12 December 2020

Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin.

1 reference

12 December 2020

[3H]zacopride binding to 5-hydroxytryptamine3 sites on partially purified rabbit enteric neuronal membranes

1 reference

12 December 2020

The serotonin type 3 receptor antagonist BRL 43694 and nausea and vomiting induced by cisplatin

1 reference

12 December 2020

Cancer Treatment Needs Better Antiemetics

1 reference

12 December 2020

Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Italian Group of Antiemetic Research

1 reference

12 December 2020

Methylprednisolone versus Metoclopramide for Prevention of Nausea and Vomiting in Breast Cancer Patients Treated with Intravenous Cyclophosphamide Methotrexate 5-Fluorouracil: A Double-Blind Randomized Study

1 reference

12 December 2020

Pattern of carboplatin-induced emesis. The German Ondansetron Study Group.

1 reference

12 December 2020

Reaction to short-term radiation in man

1 reference

12 December 2020

Comparison of the antiemetic effect of high-dose intravenous metoclopramide and high-dose intravenous haloperidol in a randomized double-blind crossover study.

1 reference

12 December 2020

A randomized cross-over study of high-dose metoclopramide plus dexamethasone versus granisetron plus dexamethasone in patients receiving chemotherapy with high-dose cisplatin.

1 reference

12 December 2020

Comparison of the antiemetic effectiveness of granisetron and alizapride plus dexamethasone in cytostatic therapy

1 reference

12 December 2020

BRL 43694: a novel antiemetic to prevent nausea and vomiting induced by chemotherapy

1 reference

12 December 2020

An open, randomized study to compare the efficacy and tolerability of tropisetron with that of a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis.

1 reference

12 December 2020

Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy

1 reference

12 December 2020

A double-blind randomized cross-over comparison of high-dose prochlorperazine with high-dose metoclopramide for cisplatin-induced emesis

1 reference

12 December 2020

High-dose metoclopramide + lorazepam versus low-dose metoclopramide + lorazepam + dehydrobenzperidol in the treatment of cisplatin-induced nausea and vomiting

1 reference

12 December 2020

Prevention of delayed emesis with metoclopramide and dexamethasone in patients receiving moderately emetogenic cytotoxic treatment

1 reference

12 December 2020

Methylprednisolone for the control of CMF-induced emesis

1 reference

12 December 2020

Methodology of antiemetic trials: a review

1 reference

12 December 2020

The effect of a susceptibility to motion sickness on the side effects of cancer chemotherapy

1 reference

12 December 2020

The role of metoclopramide in acute and delayed chemotherapy induced emesis: a randomised double blind trial

1 reference

12 December 2020

Effect of localized brain stem lesions and supradiaphragmatic vagotomy on x-irradiation emesis in the monkey.

1 reference

12 December 2020

The 5-HT3 receptor antagonist ondansetron re-establishes control in refractory emesis induced by non-cisplatin chemotherapy

1 reference

12 December 2020

Comparison of granisetron alone and granisetron plus hydroxyzine hydrochloride for prophylactic treatment of emesis induced by cisplatin chemotherapy.

1 reference

12 December 2020

Ondansetron and dexamethasone versus standard combination antiemetic therapy. A randomized trial for the prevention of acute and delayed emesis induced by cyclophosphamide-doxorubicin chemotherapy and maintenance of antiemetic effect at subsequent c

1 reference

12 December 2020

Randomized crossover antiemetic study in cisplatin-treated patients. Comparison between high-dose i.v. metoclopramide and high-dose i.v. dexamethasone

1 reference

12 December 2020

Single-agent oral granisetron for the prevention of acute cisplatin-induced emesis: a double-blind, randomized comparison with granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone

1 reference

12 December 2020

Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs

1 reference

12 December 2020

The Bötzinger complex as the pattern generator for retching and vomiting in the dog

1 reference

12 December 2020

Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine

1 reference

12 December 2020

Efficacy and tolerability of tropisetron and dexamethasone in the control of nausea and vomiting induced by cisplatin

1 reference

12 December 2020

Antiemetic effect of oral versus intravenous metoclopramide in patients receiving cisplatin: a randomized, double-blind trial

1 reference

12 December 2020

Localization of 5-HT3 receptor binding sites in human dorsal vagal complex

1 reference

12 December 2020

High-Dose Dexamethasone and High-Dose Metoclopramide versus High-Dose Dexamethasone and Sulpiride in the Management of Cisplatin-Induced Emesis

1 reference

12 December 2020

Loss of efficacy of ondansetron-dexamethasone during successive courses in female patients receiving high-dose cisplatin

1 reference

12 December 2020

Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting

1 reference

12 December 2020

The antiemetic activity of tetrahydrocannabinol versus metoclopramide and thiethylperazine in patients undergoing cancer chemotherapy

1 reference

12 December 2020

A randomized, multicenter study comparing the efficacy and tolerability of tropisetron, a new 5-HT3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis

1 reference

12 December 2020

Comparison of different schedules of ondansetron (GR 38032F) administration during cisplatin-based chemotherapy: a randomized trial

1 reference

12 December 2020

GR38032F, a 5HT3 receptor antagonist, in the prophylaxis of acute cisplatin-induced nausea and vomiting

1 reference

12 December 2020

Metoclopramide versus metoclopramide and lorazepam. Superiority of combined therapy in the control of cisplatin-induced emesis

1 reference

12 December 2020

Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. The Granisetron Study Group

1 reference

12 December 2020

The abdominal visceral innervation and the emetic reflex: pathways, pharmacology, and plasticity

1 reference

12 December 2020

Double-blind randomized cross-over trial of dexamethasone and prochlorperazine as anti-emetics for cancer chemotherapy.

1 reference

12 December 2020

Vagal afferent discharge from gastric mechanoreceptors during contraction and relaxation of the ferret corpus

1 reference

12 December 2020

Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting

1 reference

12 December 2020

A randomized, double-blind comparison of the antiemetic effect of metoclopramide and lorazepam with or without dexamethasone in patients receiving high-dose cisplatin

1 reference

12 December 2020

Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide

1 reference

12 December 2020

Oral granisetron--simple and effective: a preliminary report. The Granisetron Study Group

1 reference

12 December 2020

Ondansetron against metoclopramide/dexamethasone--a comparative study

1 reference

12 December 2020

[Granisetron, a antiemetic for treatment of cytostatic drug-induced vomiting: results of a practice-oriented study]

1 reference

12 December 2020

Antiemetic treatment with oral granisetron in patients receiving moderately emetogenic chemotherapy: a dose-ranging study

1 reference

12 December 2020

A randomized trial comparing alizapride alone or with dexamethasone vs a metoclopramide-dexamethasone combination for emesis induced by moderate-dose cisplatin

1 reference

12 December 2020

Increase in serotonin levels in the dog ileum and blood by cisplatin as measured by microdialysis

1 reference

12 December 2020

A CONTROLLED CLINICAL EVALUATION OF ANTIEMETIC DRUGS

1 reference

12 December 2020

Cisplatin-induced emesis in the Ferret: a new animal model

1 reference

12 December 2020

High-dose metoclopramide and dexamethasone as an antiemetic in outpatients receiving chemotherapy for breast cancer. Second study

1 reference

12 December 2020

Neuronal connections of the area postrema

1 reference

12 December 2020

Single, high-dose intravenous dexamethasone as an antiemetic in cancer chemotherapy

1 reference

12 December 2020

A randomized comparison of haloperidol plus dexamethasone versus prochlorperazine plus dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for breast cancer

1 reference

12 December 2020

Comparative aspects of the area postrema: fine-structural considerations help to determine its function

1 reference

12 December 2020

Continuous i.v. infusion versus multiple bolus doses of metoclopramide for prevention of cisplatin-induced emesis

1 reference

12 December 2020

A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy.

1 reference

12 December 2020

A randomised, double-blind comparison of granisetron with high-dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induced emesis. An NCI Canada Clinical Trials Group Phase III Trial

1 reference

12 December 2020

Definitional issues in the study of anticipatory nausea in cancer chemotherapy.

1 reference

12 December 2020

Combination antiemetics for cisplatin chemotherapy

1 reference

12 December 2020

Another function of the inner ear: facilitation of the emetic response to poisons

1 reference

12 December 2020

Antiemetic efficacy of high-dose dexamethasone versus placebo in patients receiving cisplatin-based chemotherapy: a randomized double-blind controlled clinical trial.

1 reference

12 December 2020

Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients. Swiss Group for Clinical Cancer Research (SAKK)

1 reference

12 December 2020

Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer

1 reference

12 December 2020

Ondansetron for nausea and vomiting associated with moderately emetogenic cancer chemotherapy

1 reference

12 December 2020

Chlorpromazine, placebo and droperidol in the treatment of nausea and vomiting associated with cisplatin therapy

1 reference

12 December 2020

Control of carboplatin-induced emesis with a fixed low dose of granisetron (0.5 mg) plus dexamethasone

1 reference

12 December 2020

Ondansetron in chemotherapy-induced emesis. Our experience

1 reference

12 December 2020

Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis

1 reference

12 December 2020

Antiemetic Efficacy of Tropisetron in Patients Failing Previous Antiemetic Therapy

1 reference

12 December 2020

Ondansetron plus dexamethasone versus metoclopramide plus dexamethasone plus diphenhydramine in cisplatin-treated patients with ovarian cancer. Italian Group for Antiemetic Research

1 reference

12 December 2020

Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy.

1 reference

12 December 2020

Observations on the release and turnover rate of 5-hydroxytryptamine in the gastrointestinal tract

1 reference

12 December 2020

5-Hydroxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis

1 reference

12 December 2020

A randomised, double-blind, parallel-group study to compare the efficacy and safety of ondansetron (GR38032F) plus dexamethasone with metoclopramide plus dexamethasone in the prophylaxis of nausea and emesis induced by carboplatin chemotherapy

1 reference

12 December 2020

A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy

1 reference

12 December 2020

Efficacy and tolerability of tropisetron in comparison with a combination of tropisetron and dexamethasone in the control of nausea and vomiting induced by cisplatin-containing chemotherapy

1 reference

12 December 2020

Cyclophosphamide, methotrexate, and 5-FU (CMF)-induced nausea and vomiting: a controlled study with high-dose metoclopramide

1 reference

12 December 2020

Modulation by 5-HT3 and 5-HT4 receptors of the release of 5-hydroxytryptamine from the guinea-pig small intestine

1 reference

12 December 2020

A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group

1 reference

12 December 2020

Observations on the connectivity of the parvicellular reticular formation with respect to a vomiting center

1 reference

12 December 2020

The efficacy of granisetron as a prophylactic anti-emetic and intervention agent in high-dose cisplatin-induced emesis

1 reference

12 December 2020

Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting

1 reference

12 December 2020

Serotonin release is mediated by muscarinic receptors on duodenal mucosal cells

1 reference

12 December 2020

The neurophysiology of vomiting

1 reference

12 December 2020

Vagal-induced vomiting in decerebrate cat is not suppressed by specific 5-HT3 receptor antagonists

1 reference

12 December 2020

Nabilone: an effective antiemetic agent in patients receiving cancer chemotherapy

1 reference

12 December 2020

Ondansetron for the control of dacarbazine-induced emesis

1 reference

12 December 2020

High-dose oral and intravenous metoclopramide in doxorubicin/cyclophosphamide-induced emesis. A randomized double-blind study

1 reference

12 December 2020

Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial

1 reference

12 December 2020

Site of emetic action of x-radiation in the cat

1 reference

12 December 2020

Effective Control of CMF-Related Emesis with High-Dose Dexamethasone

1 reference

12 December 2020

Management of cyclophosphamide-induced emesis over repeat courses.

1 reference

12 December 2020

[Tropisetron versus ondansetron in the prevention and control of emesis in patients undergoing chemotherapy with FAC/FEC for metastatic or surgically treated breast carcinoma].

1 reference

12 December 2020

[Ondansetron (GR 38032F), a competitive 5-HT3 receptor antagonist as an antiemetic in cytostatic drug-induced nausea and vomiting. An open, substance-oriented phase II/III study]

1 reference

12 December 2020

Optimal combination therapy with tropisetron in 445 patients with incomplete control of chemotherapy-induced nausea and vomiting.

1 reference

12 December 2020

Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis.

1 reference

12 December 2020

Prochlorperazine and transdermal scopolamine added to a metoclopramide antiemetic regimen. A controlled comparison

1 reference

12 December 2020

Psycho-social correlates of nausea and vomiting in pregnancy

1 reference

12 December 2020

Selective blockade of cytotoxic drug-induced emesis by 5-HT3 receptor antagonists in Suncus murinus

1 reference

12 December 2020

Delimitation of central nervous mechanisms involved in motion sickness

1 reference

12 December 2020

Evidence that neuronally released vasoactive intestinal polypeptide inhibits the release of serotonin from enterochromaffin cells of the guinea pig small intestine.

1 reference

12 December 2020

Antiemetic combination for PAC (cisplatin-adriamycin-cyclophosphamide) chemotherapy-induced emesis in ovarian cancer

1 reference

12 December 2020

Distribution of 5-hydroxytryptamine (serotonin, enteramine) in the wall of the digestive tract

1 reference

12 December 2020

First results with ICS 205-930 (5-HT3 receptor antagonist) in prevention of chemotherapy-induced emesis

1 reference

12 December 2020

Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study.

1 reference

12 December 2020

Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients.

1 reference

12 December 2020

Methylprednisolone as an antiemetic during cancer chemotherapy--a pilot study

1 reference

12 December 2020

Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting

1 reference

12 December 2020

Prognostic factors influencing cisplatin-induced emesis. Definition and validation of a predictive logistic model

1 reference

12 December 2020

Antiemetic activity of metoclopramide versus alizapride during cancer chemotherapy

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03041988

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19479418%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference